Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

In Vivo Pharmacology

The in vivo pharmacology arm of the Sygnature Group, RenaSci, provides an integrated blend of consultancy and experimental services to clients from all sectors of the pharmaceutical industry to help maximise research productivity and streamline drug development.

The company was established in 2001 and specialises in the following key areas:

  • Abuse & Dependence
  • CNS
  • Obesity
  • Diabetes
  • NASH
  • Kidney Disease

RenaSci’s clients include pharma, biotech and virtual companies and healthcare investors from the UK, mainland Europe, USA and Japan, and they collaborate with their clients on all stages of the drug development process from target identification to post registration.

Their regulatory expertise combined with skills in drug development and abuse liability assessments have been pivotal to the success of clients in achieving European and US drug registrations. They have facilitated more than 30 NCE’s into clinical development and 10 drugs to the market.

Working arrangements with their sponsors range from one off fee-for-service studies through to long term FTE arrangements to ensure the continuity of project work. The fact that RenaSci have worked with some of their clients for many years and that many of them are returning customers is testament to the high quality of their service.

For more information on RenaSci, and the services they offer, follow the link below: 

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.